{"id":"NCT02452866","sponsor":"Symbiomix Therapeutics","briefTitle":"Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219","officialTitle":"Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2015-05-25","resultsPosted":"2021-04-13","lastUpdate":"2021-04-13"},"enrollment":325,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Vaginosis"],"interventions":[{"type":"DRUG","name":"SYM-1219","otherNames":["Secnidazole"]}],"arms":[{"label":"SYM-1219","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent girls with bacterial vaginosis.","primaryOutcome":{"measure":"Numbers of Participants With Treatment Emergent Adverse Events and Laboratory Abnormalities","timeFrame":"30days","effectByArm":[{"arm":"SYM-1219","deltaMin":95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":321},"commonTop":["Vulvovaginal mycotic infection","Urinary tract infection","Vulvovaginal candidiasis","Bacterial vaginosis","Nasopharyngitis"]}}